Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Presentation

Preclinical Development of a Novel Gene Therapy for the Treatment of Peripheral Neuropathic Pain Through Zinc Finger Repressor- Mediated Repression of the SCN9A Gene

Download PDF